
    
      This phase II study will assess the clinical response rate to Ibritumomab Tiuxetan in
      patients with untreated nodal, splenic and non-gastric extranodal MZL as well as in
      antibiotic resistant patients with mucosa-associated lymphoid tissue (MALT) gastric lymphoma.
    
  